|Tel||+44 (0)1865 617498|
I undertook my undergraduate medical training at the University of Sheffield, where I completed an intercalated BMedSci degree in pathology in 1995, and qualified in 1998. After completing Basic Surgical Training in South Yorkshire in 2003, I was awarded a Medical Research Council Fellowship (2004-2007) and undertook a PhD researching molecular mechanisms of prostate cancer progression. I then undertook higher surgical training in Urology in both Sheffield and Oxford, whilst in parallel continuing to pursue my prostate cancer research interests, leading to numerous scientific publications in this field under the mentorship of Professor Freddie Hamdy. In 2015, I was appointed Locum Consultant Urologist in Oxford and continued to combine clinical practice, specialising in the diagnosis and management of prostate cancer, with prostate cancer research. In 2017 I was appointed Honorary Consultant Urologist in Oxford.
Cancer Research UK / Royal College of Surgeons of England Clinician Scientist Fellow
- Honorary Urology Consultant
I am a Cancer Research UK Clinician Scientist Fellow (joint with the Royal College of Surgeons of England), which enables me to continue to combine my care of prostate cancer patients with a wide and growing prostate cancer research portfolio, covering the breadth of basic science, translational, and clinical research, at the Nuffield Department of Surgical Sciences.
I have been the Lead Clinician for the VANCE (VAcciNation in prostate CancEr) Clinical trial in Oxford since 2015, and in 2017 I commenced my current position as Honorary Consultant Urologist at the Churchill Hospital in Oxford.
I also deliver undergraduate teaching in surgery and urology to clinical medical students.
- Executive committee member of the Academic Section of the British Association of Urological Surgeons (BAUS) (2017-2019)
- Full member of BAUS, the European Urology Association (EAU), and the American Urology Association (AUA)
Altered expression of epithelial-to-mesenchymal transition proteins in extraprostatic prostate cancer.
Verrill C. et al, (2016), Oncotarget, 7, 1107 - 1119
Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
Bryant RJ. et al, (2015), J Natl Cancer Inst, 107
Variation between specialist uropatholgists in reporting extraprostatic extension after radical prostatectomy.
Bryant RJ. et al, (2015), J Clin Pathol, 68, 465 - 472
The genomic diversity of prostate cancer: our Achilles heel explored.
Bryant RJ. et al, (2015), Eur Urol, 67, 823 - 824
Nuclear iASPP may facilitate prostate cancer progression.
Morris EV. et al, (2014), Cell Death Dis, 5